Thursday, 15 October 2026European Markets

MYHOTELMATCH Stock Over 27% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of myhotelmatch (cac 40: mhm.pa) dropped by a staggering 27.01% in 10 sessions from €0.03 to €0.02 at 11:06 est on thursday, after five successive sessions in a row of losses. cac 40 is falling 1.21% to €7,172.96, after three sequential sessions in a row of losses.

myhotelmatch's last close was €0.02, 40.21% under its 52-week high of €0.04.

about myhotelmatch

myhotelmatch s.a. engages in the development and exploitation of an online hotel reservation platform based on artificial intelligence (ai). it operates as an online travel agency based on the principle of online dating. the company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. the company is based in biot, france.

earnings per share

as for profitability, myhotelmatch has a trailing twelve months eps of €-0.04.

moving average

myhotelmatch's value is way below its 50-day moving average of €0.03 and under its 200-day moving average of €0.02.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, myhotelmatch's stock is considered to be overbought (>=80).

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com